Rituximab performs well in new-onset myasthenia gravis

Early treatment with rituximab may be associated with improved outcomes in patients with new-onset generalised myasthenia gravis (MG), according to a study published in JAMA Neurology. The Swedish study of 72 patients, identified through the country’s MG registry, suggests the B-cell–depleting monoclonal antibody might be more effective than conventional immunosuppressants and could be used earlier ...

Already a member?

Login to keep reading.

© 2021 the limbic